ABVC BioPharma, Inc. Common Stock
ABVCStock
$1.21−61.82%52W
Market Cap$33.28M
P/E—
Div yield—
Beta0.61
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-49.65%
Price vs S&P 500 (4W)6.75%
VGM Score36.79
Market Capitalization$33.28M
Analyst Recommendations
Jul 2023
Aug 2023
Sep 2023
Oct 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABVCABVC BioPharma, Inc. Common Stock | D | B | D | $1.21 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ABVC BioPharma is a clinical-stage biopharmaceutical company developing a pipeline of six drug candidates and a medical device based on botanically-derived therapeutics. The company focuses on proof-of-concept and Phase II clinical trials, leveraging proprietary technology to deliver high efficacy with low toxicity profiles.